| For: | de Salins V, Loganadane G, Joly C, Abulizi M, Nourieh M, Boussion H, Belkacemi Y, Tournigand C, Kempf E. Complete response in anaplastic lymphoma kinase–rearranged oncocytic thyroid cancer: A case report and review of literature. World J Clin Oncol 2020; 11(7): 495-503 [PMID: 32821654 DOI: 10.5306/wjco.v11.i7.495] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v11/i7/495.htm |
| Number | Citing Articles |
| 1 |
Viktoria F. Koehler, C. Benedikt Westphalen, James Nagarajah, Mathias Zacherl, Christine Spitzweg. Molekular zielgerichtete Therapien beim radiojodrefraktären differenzierten Schilddrüsenkarzinom – Update 2022. Die Onkologie 2022; 28(8) doi: 10.1007/s00761-022-01195-8
|
| 2 |
Ariadna Tibau, Thomas J Hwang, Jerry Avorn, Aaron S Kesselheim. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ 2024; 386 doi: 10.1136/bmj-2023-079126
|
| 3 |
Carrie C. Lubitz, Peter M. Sadow, Gilbert H. Daniels, Lori J. Wirth. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy. Thyroid 2021; doi: 10.1089/thy.2020.0962
|
| 4 |
Ying-Hsia Chu. This is Your Thyroid on Drugs. Surgical Pathology Clinics 2023; 16(1) doi: 10.1016/j.path.2022.09.007
|
| 5 |
Karen M. Yun, Ezra E.W. Cohen. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer. JCO Oncology Practice 2024; 20(7) doi: 10.1200/OP.23.00747
|
| 6 |
Jesús Yaringaño, Jorge Hernando, Alejandro García-Álvarez, Carmela Iglesias-Felip, Carles Zafón, Ana Vivancos, María Roca-Herrera, Sergio Pérez-Fernández, Sandra Martínez-Badal, Belén Elguero, Jaume Capdevila. Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor. Frontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1802225
|
| 7 |
Matti L. Gild, Martyn Bullock, Venessa Tsang, Roderick J. Clifton-Bligh, Bruce G. Robinson, Lori J. Wirth. Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics. Thyroid 2023; 33(6) doi: 10.1089/thy.2022.0704
|
| 8 |
Ignacio Ruz-Caracuel, Teresa Alonso-Gordoa, Susana Hernández, Jorge Hernando, Maria Teresa Rodrigo-Calvo, Paula Jimenez-Fonseca, Hernán Dario Quiceno-Arias, Isabel Lorenzo-Lorenzo, María Rosa Bella-Cueto, Carmela Iglesias, José Manuel Cameselle-Teijeiro, Jaume Capdevila. SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer. Revista Española de Patología 2026; 59(2) doi: 10.1016/j.patol.2026.100859
|
| 9 |
Kajetan Kiełbowski, Justyna Żychowska, Rafał Becht. Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1285374
|
| 10 |
YiHeng Yang, YeSheng Zhang, YongCan Xu, XiaoXin Gu, Neng Lou, GuoChao Ye. Targeted therapy in thyroid cancer: molecular alterations and clinical management. Frontiers in Endocrinology 2026; 17 doi: 10.3389/fendo.2026.1810813
|
| 11 |
|
| 12 |
Lucheng Zhu, Shenglin Ma, Bing Xia. Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1009076
|
| 13 |
Ying-Hsia Chu, Peter M. Sadow. Kinase Fusion–Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics. Endocrine Pathology 2022; 33(4) doi: 10.1007/s12022-022-09739-9
|
| 14 |
Sabrina K. Salgia, Ameish Govindarajan, Ravi Salgia, Sumanta K. Pal. ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?. JCO Precision Oncology 2021; (5) doi: 10.1200/PO.21.00078
|
| 15 |
Elisabetta Macerola, Anello Marcello Poma, Paola Vignali, Agnese Proietti, Clara Ugolini, Liborio Torregrossa, Alessio Basolo, Rossella Elisei, Ferruccio Santini, Fulvio Basolo. Predictive Biomarkers in Thyroid Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.901004
|
| 16 |
Matthew D. Ringel, Julie Ann Sosa, Zubair Baloch, Lindsay Bischoff, Gary Bloom, Gregory A. Brent, Pamela L. Brock, Roger Chou, Robert R. Flavell, Whitney Goldner, Elizabeth G. Grubbs, Megan Haymart, Steven M. Larson, Angela M. Leung, Joseph R. Osborne, John A. Ridge, Bruce Robinson, David L. Steward, Ralph P. Tufano, Lori J. Wirth. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid® 2025; 35(8) doi: 10.1177/10507256251363120
|
| 17 |
Ying-Hsia Chu, Peter M. Sadow. Kinase fusion-related thyroid carcinomas: distinct pathologic entities with evolving diagnostic implications. Diagnostic Histopathology 2021; 27(6) doi: 10.1016/j.mpdhp.2021.03.003
|
| 18 |
Simion Chiosea, Steven P Hodak, Linwah Yip, Devaprabu Abraham, Chelsey Baldwin, Zubair Baloch, Seza A Gulec, Zeina C Hannoush, Bryan R Haugen, Lija Joseph, Atil Y Kargi, Elham Khanafshar, Masha J Livhits, Bryan McIver, Kepal Patel, Snehal G Patel, Gregory W Randolph, Ashok R Shaha, Jyotirmay Sharma, Nikolaos Stathatos, Annemieke van Zante, Sally E Carty, Yuri E Nikiforov, Marina N Nikiforova. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management. The Journal of Clinical Endocrinology & Metabolism 2023; 108(11) doi: 10.1210/clinem/dgad220
|
| 19 |
Debora Mota Dias Thomaz, Thais Biude Mendes, Thaise Nayane Ribeiro Carneiro, Luiza Sisdelli, Ana Carolina de Jesus Paniza, André Uchimura Bastos, Janete Maria Cerutti. Distinct ALK Expression Patterns Are Associated with Canonical and Noncanonical STRN::ALK Transcript Architectures in Oncocytic Thyroid Neoplasms. Endocrine Pathology 2026; 37(1) doi: 10.1007/s12022-026-09924-0
|
| 20 |
Young Kee Shong. Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer. International Journal of Thyroidology 2021; 14(2) doi: 10.11106/ijt.2021.14.2.98
|
| 21 |
Svetlana N. Aleksakhina, Evgeny N. Imyanitov. Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. International Journal of Molecular Sciences 2021; 22(20) doi: 10.3390/ijms222010931
|
| 22 |
Alyaksandr V. Nikitski, Vincenzo Condello, Saurabh S. Divakaran, Yuri E. Nikiforov. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells. Thyroid® 2023; 33(4) doi: 10.1089/thy.2022.0533
|
| 23 |
Hervé Bischoff, Antonin Fattori, Fabien Moinard-Butot, Olivier Schneegans, Pablo Diaz, Damien Reita, Valérie Rimelen, Anne-Claire Voegeli, Laura Bender. First Report of SPECC1L::ALK Fusion in Medullary Thyroid Carcinoma with Remarkable Response to Alectinib. Thyroid® 2025; doi: 10.1089/thy.2025.0017
|
| 24 |
Geethu Babu, Rejnish Ravikumar, Malu Rafi, Lekha Madhavan Nair, Zuzaki Sharafuddin, John Mathew, Nijo Jose, Kainickal Cessal Thommachan. Thyroid Cancer - The Road From Genes to Successful Treatment. 2023; doi: 10.5772/intechopen.106462
|
| 25 |
Amr H. Abdelhamid Ahmed, Marika D. Russell, Gregory W. Randolph. Controversies in Cancer of the Thyroid and Parathyroid Glands. 2026; doi: 10.1007/978-3-032-13130-0_16
|
| 26 |
Silvia Buriolla, Giulia Zapelloni, Claudia Cipri, Giacomo Pelizzari, Alessandro Follador, Francesco Cortiula. Alectinib for the treatment of papillary thyroid carcinoma harbouring STRN – ALK fusion. European Journal of Cancer 2025; 216 doi: 10.1016/j.ejca.2024.115193
|